All Outputs (5)

Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial (2023)
Presentation / Conference
Roffe, C., Warusevitane, A., Smith, C., Dixit, A., Sprigg, N., Ogollah, R., …Bath, P. (2023, October). Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial. Poster presented at 15th World Stroke Congress, Toronto, Canada

The research study is designed to assess a treatment which might prevent pneumonia and improve survival in patients that have had a stroke. Pneumonia is a major cause of death after stroke and delays recovery in survivors. The most important cause o... Read More about Metoclopramide for Avoiding Pneumonia after Stroke (MAPS-2) Trial.

Stroke survivors' self-management of life-career transitions (2022)
Presentation / Conference
Wilson, C., Roffe, C., Spires, J., & Weston, S. (2022, November). Stroke survivors' self-management of life-career transitions. Presented at 17th UK Stroke Forum, Liverpool ACC, UK

Adult-onset mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS): a diagnostic challenge (2022)
Presentation / Conference
Acquaah, J., Roffe, C., & Ferdinand, P. (2022, November). Adult-onset mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS): a diagnostic challenge. Presented at 17th UK Stroke Forum, Liverpool ACC, UK

THE METOCLOPRAMIDE FOR AVOIDING PNEUMONIA AFTER STROKE (MAPS-2) TRIAL: A SINGLE-BLIND RCT OF METOCLOPRAMIDE FOR THE PREVENTION OF PNEUMONIA IN PATIENTS WITH DYSPHAGIA AFTER STROKE (2021)
Presentation / Conference
Roffe, C., Bath, P., Warusevitane, A., Smith, C., Dixit, A., Sprigg, N., …Ogollah, R. (2021, November). THE METOCLOPRAMIDE FOR AVOIDING PNEUMONIA AFTER STROKE (MAPS-2) TRIAL: A SINGLE-BLIND RCT OF METOCLOPRAMIDE FOR THE PREVENTION OF PNEUMONIA IN PATIENTS WITH DYSPHAGIA AFTER STROKE. Presented at UK Stroke Forum 2021, Virtual

THE EFFECT OF INTRAVENOUS THROMBOLYSIS WITHIN 6 HOURS OF STROKE ONSET ON DISCHARGE DESTINATION, THE ABILITY TO WALK AND TALK, AND QUALITY OF LIFE IN PATIENTS OVER THE AGE OF 80 YEARS IN THE THIRD INTERNATIONAL STROKE TRIAL (IST-3) (2013)
Presentation / Conference
Roffe, C. (2013, November). THE EFFECT OF INTRAVENOUS THROMBOLYSIS WITHIN 6 HOURS OF STROKE ONSET ON DISCHARGE DESTINATION, THE ABILITY TO WALK AND TALK, AND QUALITY OF LIFE IN PATIENTS OVER THE AGE OF 80 YEARS IN THE THIRD INTERNATIONAL STROKE TRIAL (IST-3). Presented at Communications to the British Geriatrics Society Autumn Meeting, Harrogate